BioLineRx Ltd. announced that an abstract including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial was accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. Updated results of the pilot study portion of the Phase 2 study include a new analysis of paired pre- and on-treatment biopsy samples that demonstrated an increase in CD8+ T-cell density in tumors from all 11 patients treated with the combination of motixafortide, cemiplimab and standard-of-care chemotherapies gemcitabine and nab-paclitaxel (P = 0.007).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16 ILa | -1.84% |
|
-6.98% | -58.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.12% | 51.46M | |
+15.19% | 122B | |
+19.91% | 113B | |
+8.24% | 22.84B | |
-19.80% | 20.72B | |
-16.19% | 16.51B | |
-13.45% | 16.39B | |
-44.35% | 15.83B | |
+2.13% | 13.49B | |
+66.67% | 11.67B |
- Stock Market
- Equities
- BLRX Stock
- News BioLineRx Ltd.
- BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology